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side of Europe. Conventional cTn algorithms, require longer waiting
times and serial measurements up to 6–12 h after presentation.
Copeptin has been suggested as a potential biomarker to evaluate
patients with acute chest pain and to safely rule-out patients in the
ED.While cTn is released into the circulation in a time-dependent fash-
ion, elevations of copeptin occur very early in AMI [2,3]. Since the initialSeveral new biomarkers have been described to improve diagnostic (DMS), currently supported by several robust studies [6,7]. However,accuracy of many diseases. Copeptin is produced in the neurohypophy-
sis and is a stable peptide derived from the C-terminal part of the argi-
nine vasopressin prohormone [1]. Vasopressin has a very short half-
life and it is very difficult to measure being copeptin an alternative
quantitative biomarker, because it is released in a proportional manner
with biologically active vasopressin [1]. Copeptin plasma concentrations
increase in response to endogenous stress in several clinical situations
including acute cardiovascular conditions, such as acute myocardial
infarction (AMI), myocarditis and heart failure [2–4]. However, it lacks
specificity because it can also increase in other non-cardiac acute situa-
tions. It is used as a non-specificmarker of acute and severe disease. As a
single variable, it has only modest accuracy for AMI.
A rapid rule-in and rule-out strategy in the emergency department
(ED) is highly desirable, particularly in non-ST elevation AMI. Not only
because it can speed the treatment but also because patients without
AMI can be discharged earlier, reducing important constrains in the
ED, such as crowding and substantial use of resources (prolonged ECG
monitoring and serial blood draws). Recently, several algorithms have
been validated and are currently recommended in European guidelines
[5]. High sensitivity cardiac troponins (hs-cTn) are the recommended
biomarkers and patients can be safely ruled-out within 1 to 3 h after
hospital admission. However, conventional and less sensitive cTn assays.2018.10.084.
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liability and freedom from biasobservations by Reichlin that copeptin is associated with AMI, several
studies tested the feasibility and safety of a dual-marker strategy
the sensitivity of the cTn assay can determine the incremental clinical
value of copeptin [2,7–9]. In fact, the incremental benefit has only
been confirmed with conventional cTn, and it was minor with more
sensitive assays. Also, the area under curve of copeptin in combination
with hc-cTn at presentation is lower when compared to hs-cTn alone
at presentation and 1 h after ED presentation. These results showed
that copeptin was only effective when less sensitive conventional cTn
were used. Due to the lack of evidence to demonstrate that there was
a significant benefit with the DMS with hs-cTn, the use of copeptin
was only recommended with lower sensitivity troponins. A DMS of
cTn level below the 99th percentile and a copeptin level below
10 pmol/L has a very high negative predictive value, particularly when
used in conjunction with full clinical assessment, including a 12-lead
ECG [6–8]. Studies that tested hs-cTn with a cut-off value below the
99th percentile showed the same negative predictive value as the com-
bination of hs-cTn at the 99th percentile together with a negative
copeptin [8,9]. When using the 99th percentile as cut-off value for
hs-cTn, it is required further studies to convincingly established a clini-
cally relevant increase in diagnostic performance with a DMS to justify
routine clinical use. The cut-off value for copeptin is also a matter of
debate. Whit the first-generation assays, the recommended cut-off
was 14 pmol/L. With more recent and higher sensitivity assays, a cut-
off of 10 pmol/L is recommended [2].
In the present issue of International Journal of Cardiology, Mueller-
Hennessen et al presented a manuscript that compares a combined
DMS with copeptin and hs-cTnT (99th percentile) at presentation
with other rapid rule-out algorithms in 922 patients presenting to the
ED with suspected AMI [10]. The authors tested several cut-offs for
both copeptin and hs-cTnT. They showed lower rule-out rates with
the DMS and higher negative predictive values and sensitivities,
272 Editorialparticularly in comparison with the hs-cTnT 99th percentile. However,
addition of clinical risk criteria allowed an increase in sensitivity up to
100% but also with significant reductions in rule-out rates. All strategies
were safe,with very lowevent rates (0.2–0.3%) at 30-day follow-up. The
authors concluded that a DMSmight be an alternative, but it depends on
the applied copeptin cut-off (with higher rule-out rates with the cut-off
of 20 pmol/L, with similar negative predictive values) and addition of
clinical low-risk criteria.
There are however presently, several important barriers for the
implementation of this strategy. Currently, this requires two different
diagnostic platforms to measure both hs-cTnT and copeptin. This is an
important inconvenient because it requires an additional analyzer.
Also, the time span between blood draw and results availability might
take longer than the time required for other rule-out algorithms. In
theory, and if these problems are solved in a near future, this DMS
is possibly associated with cost savings. However, the exact cost-
effectiveness is unknown.Adequately designed health economic studies
are needed to address this subject.
Another important point to mention is that this study confirmed the
importance of adequate clinical judgment for a correct rule-out. The
inclusion of clinical criteria increased the negative predictive value
and sensitivity. For that reason, it is important that independently of
the strategy chosen, all clinical information must be appropriately
assessed by ED physicians (including detailed assessment of chest
pain and the ECG) to avoid inappropriate rule-out and discharge of
AMI patients. Another important point is that copeptin does not
increase in the presence of unstable angina [2]. Therefore, if we rule-
out AMI, it does not mean that the patients do not have significant
coronary artery disease, and if symptoms are typical, further testing
might be warranted, usually in an ambulatory setting.
With the present data, we can conclude that a DMS with copeptin
and hs-cTnT might be useful, but it is not ready yet to be implemented
in routine clinical practice. It requires comprehensive health economic
analysis and practical solutions regarding laboratory testing.Conflict of interests
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